ClinicalTrials.gg
CompletedNCT05990660BIPASS-AKIUpdated Jan 23, 2024

Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery

An interventional study of JuxtaFlow System in Renal Insufficiency and Acute Kidney Injury, sponsored by 3ive Labs. Completed at 3 sites in 2 countries. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-23.

Primary conditionAcute Kidney InjuryRegistry: Renal InsufficiencyReclassifiedWhy we changed it
Registry
Renal Insufficiency — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acute Kidney Injury
Why
  1. The study's listed conditions name Acute Kidney Injury, a narrower term within Renal Insufficiency.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by 3ive Labs · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
22 Years to 85 Years
Sex
All
01

Study summary

The study is a prospective, non-randomized early feasibility study intended to evaluate the safety and performance of the JuxtaFlow System (also known as the JuxtaFlow Renal Assist Device (RAD)) in participants with pre-existing renal insufficiency who are undergoing cardiac surgery.

Read the detailed description

The BIPASS-AKI study is intended to evaluate participants who are at an increased risk of developing cardiac surgery-associated acute kidney injury (CSA-AKI), and, subsequently, overall poor outcomes. Patients to be considered for participation include those undergoing elective or urgent in-house on-pump cardiac surgery (to include coronary artery bypass graft, valvular surgery, or combination) and have pre-existing renal insufficiency as defined by a pre-operative eGFR between 15-60 mL/min. Participants meeting inclusion and exclusion criteria will be enrolled into a treatment arm (single-arm study) following the completion of informed consent. Participants will receive implantation of the JuxtaFlow Catheters following completion of the their cardiac surgery while remaining under anesthesia. Treatment with the JuxtaFlow System will be initiated upon the participant's arrival into the intensive care unit and continue for up to 24 hours post-operatively. Preoperative, intra-operative, and post-operative data will be collected on participants to include 15- and 30-day follow-up periods.

02

Conditions studied

  • Renal Insufficiency
  • Acute Kidney Injury

Browse trials for

Keywords

  • Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI)
  • Renal Compromise
  • Kidney Disease
  • Cardiopulmonary Bypass
  • Renal Assist Device (RAD)
  • Cardiac Surgery
03

In context

Acute Kidney Injury Reclassified

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

This study's enrollment of 10 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

3ive Labs is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Acute Kidney Injury, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Candidate cardiac surgical patients
  2. Elective or Urgent on-pump coronary artery bypass grafting (CABG) and/or valvular surgery
  3. Age 22 to 85 years
  4. \< 60 mL/min/1.73m2
  5. Signed

Exclusion criteria

Exclusion Criteria:

  1. End-stage renal disease (receiving hemodialysis or \<15 ml/min/1.73m2)
  2. Planned off-pump surgery
  3. Any patients with high-grade proteinuria (i.e., urine protein concentration > 300 mg/dL)
  4. Pregnancy
  5. Any secondary condition as determined by the investigator that would place the subject at an increased risk, or preclude the subject's full compliance with the study procedures, including injuries to the urinary organs and/or external genitals
  6. Current or planned treatment with an drug (IND), device (IDE), or other investigational intervention within 3 months prior to or during participation in this clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Treatment

    Device: JuxtaFlow System

Interventions

  • DeviceJuxtaFlow System

    Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters

06

What researchers measure

Primary outcomes

  1. [Safety] Adverse Events Characterization

    The characterization of all type, frequency, severity, and device-relatedness of the adverse events (AEs) associated with the placement, use, and removal of the JuxtaFlow System for the treatment of renal insufficiency in cardiac surgery patients.

    Time frame: 30 days

  2. [Efficacy] Creatinine Clearance

    The change in measured creatinine clearance occurring over the treatment period of 24 hours or less.

    Time frame: 24 hours

  3. [Efficacy] Urine Sodium Excretion

    The change in urine sodium excretion occurring over the treatment period of 24 hours or less.

    Time frame: 24 hours

07

Study locations

3 sites
  • Polsko-Amerykanskie Kliniki Serca, Centrum Kardiologii
    Kraków, Bielsko-Biata 43-316, Poland
  • Institute for Cardiovascular Diseases "Dedinje"
    Belgrade, Serbia
  • Institute of Cardiovascular Diseases of Vojvodina
    Sremska Kamenica, Serbia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2023, 3 months.

Of 269 interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 14, 2023
StartActual
Sep 28, 2023
Primary completionActual
Dec 28, 2023
CompletionActual
Jan 18, 2024
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05990660
Lead sponsor
3ive Labs
Collaborators
SCIRENT
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Sep 28, 2023
Primary completion
Dec 28, 2023
Completion
Jan 18, 2024
Last update
Jan 23, 2024

Study contacts

Slobodan Micovic, MD
principal investigator · Institute for Cardiovascular Diseases Dedinje
Milovan Petrovic, MD
principal investigator · Institute of Cardiovascular Diseases of Vojvodina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion